PROTEASE INHIBITORS USED IN THE TREATMENT OF HIV+ INDUCE BETA-CELL

用于治疗艾滋病毒的蛋白酶抑制剂诱导β细胞

• 批准号: 8361416
• 负责人: Sheng Zhang
• 金额: $ 2.98万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361416
• 关键词: Beta Cell; Funding; Grant; HIV; HIV Protease Inhibitors; Incidence; Life; Mass Spectrum Analysis; Metabolic; National Center for Research Resources; Principal Investigator; Protease Inhibitor; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; biomedical resource; cost; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Inclusion of HIV protease inhibitors (PIs) in the treatment of people living with HIV+ has markedly decreased mortality but also increased the incidence of metabolic abnormalities, causes of which are not well understood.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 在艾滋病毒阳性患者的治疗中加入艾滋病毒蛋白酶抑制剂（PI），显著降低了死亡率，但也增加了代谢异常的发生率，其原因尚不清楚。